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Abstract
Background: The formation of metastases includes the separation of tumor cells from the primary tumor, cell
migration into subendothelial tissue and cell proliferation in secondary organ. In this process, cell adhesion of
tumor cells to the endothelium is an essential requirement for formation of metastases. Protein kinase C (PKC)
regulates adhesion and proliferation. To identify a relation between PKC isoforms and tumor progression in renal
cell carcinoma (RCC), the influence of PKC isoforms on cell adhesion and proliferation, and possible influences of
integrins were analyzed in RCC cells.
Methods: The experiments were performed in the RCC cell lines CCF-RC1 and CCF-RC2 after pre-incubation (16 h)
with the PKC inhibitors GF109203X (inhibits PKCa, bI, bII, g, δ and ε), GÖ6976 (inhibits PKCa, bI and μ), RO31-8220
(inhibits PKCa, bI, bII, g and ε) and rottlerin (inhibits PKCδ). Cell adhesion was assessed through adherence of RCC
cells to an endothelial monolayer. Cell proliferation was analyzed by a BrdU incorporation assay. The expression of
b1 integrins was analyzed by flow cytometry.
Results: In CCF-RC1 cells, cell adhesion was significantly reduced by GÖ6976 to 55% and by RO31-8220 to 45% of
control. In CCF-RC2 cells, only GÖ6976 induced a significant reduction of cell adhesion to 50% of control levels.
Proliferation of both cell lines was reduced by rottlerin to 39% and 45% of control, respectively. The b1 integrin
expression on the cell surface of CCF-RC1 and CCR-RC2 cells was decreased by RO31-8220 to 8% and 7% of
control, respectively. b2 and b3 integrins were undetectable in both cell lines.
Conclusions: The combination of the PKC inhibitors leads to the assumption that PKCμ influences cell adhesion in
CCF-RC1 and CCF-RC2 cells, whereas in CCF-RC1 cells PKCε also seems to be involved in this process. The
expression of b1 integrins appears to be regulated in particular by PKCε. Cell proliferation was inhibited by rottlerin,
so that PKCδ might be involved in cell proliferation in these cells.
Background
Formation of metastases includes the separation of sin-
gle cells from the primary tumor, migration into the
extracellular matrix, blood vessel invasion, adhesion to
endothelium, migration through the endothelium and
growth in a secondary organ [1]. During extravasation
into the secondary organ, tumor cells seem to undergo
the same mechanisms as leukocytes in inflammatory
processes. After a loose contact to endothelial cells,
integrins on the cell surface of leukocytes become acti-
vated by a chemokine induced inside-out signaling
sought by endothelial cells [2] or by direct cell-cell
contact [3]. Activated integrins, in particular b1, b2a n d
b3 integrins, mediate a firm adhesion to endothelial
cells by binding their ligands such as ICAM, VCAM,
PECAM or other integrins [4-6] leading to transen-
dothelial migration. In the process of metastases, the
adhesion of tumor cells to endothelial cells has also
been shown to be mediated by integrins. The tumor
cells bind their ligands, located on the cell surface of
endothelial cells, leading to a firm adhesion, and subse-
quently to transendothelial migration. In vitro experi-
ments showed a major importance in the binding of
a4b1 integrin to VCAM in several tumor entities in
tumor cell adhesion [7,8]. Furthermore, a6b1, avb1a n d
avb3 integrins have been shown to be involved in
tumor cell-endothelial cell adhesion [9-11].
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been demonstrated for b1 integrins [12,13]. The func-
tion of integrins can rapidly be changed by altering their
binding affinity for ligands through inside-out signaling.
Inside-out signaling induces a conformational change
from the cytoplasmic domains in the direction of the
extracellular binding site, in response to intracellular
signaling events. Signaling molecules involved in inside-
out signaling of integrins are G proteins, Ca
2+, phospho-
lipase, tyrosine kinase, CaM kinase II, and protein
kinases C (PKCs) [14-16]. The activation pathway on
integrins by PKC includes RACK (receptor for activated
C kinase), which binds to the b subunit of integrins
[17]. PKC modulation results in an alteration of the
integrin avidity and affinity [18]. In addition to the activ-
ity of integrins, PKC regulates the integrin expression on
the cell surface [19,20]. These reports demonstrate the
interaction between PKC and integrins.
The family of PKC comprises phospholipid dependent
serine/threonine protein kinases deriving from different
PKC genes, and from alternative splicing of a single
transcript [21]. Up to 10 distinct family members have
been discovered in mammalian cells, which are classified
into Ca
2+-dependent conventional cPKC isoforms a, bI,
bII and g,C a
2+-independent novel nPKCs δ, ε, h and θ,
and the atypical aPKCs l/τ and ζ.P K C μ/PKD, a Ca
2+
independent PKC with a unique substrate specificity
which differs from the PKC isoforms [22], has primary
been related to the PKC family, but cannot be attributed
as a member of the PKC family. In contrast to the PKC
family, which belongs to the AGC group (PKA, PKG,
PKC), PKCμ belongs to the CAMK group (Calcium/cal-
modulin-dependent protein kinase) [23,24]. The expres-
sion patterns of PKC isoforms differ between tissues
and the subcellular distribution of the isoforms varies
depending on cell type and physiological condition
[25-27], so that an overexpression of the same PKC iso-
form in different cells may result in opposite biological
effects, depending on the cell type [28,29].
To date, little is known about the isoform specific role
of PKC in metastasis of renal cancer. To answer this
question, we investigated the influence of different-iso-
form specific PKC inhibitors on the metastatic behavior
of renal carcinoma cells in vitro. Consequently, the
involvement of PKC in the adhesion of renal tumor
cells, as well as cell proliferation and the expression of
integrins was analyzed.
Methods
Cells and cell culture
The human renal carcinoma cell lines CCF-RC1 and
CCF-RC2 were used for all experiments. CCF-RC1 was
isolated from a high grade pleomorphic renal cell carci-
noma (nuclear grade 3) [30,12], CCF-RC2 was cultured
from the effluent of the same kidney. Cell culture was
maintained in RPMI 1640 with L-glutamine (Gibco,
Eggenstein, Germany), supplemented with 10% fetal calf
serum and 0.5% penicillin/streptomycin (Gibco, Eggen-
stein, Germany). The cells were incubated at 37°C in a
humidified atmosphere containing 5% CO2 in air. Cells
in the present study were used between passage 20 and
30.
For cell adhesion experiments, human umbilical vein
endothelial cells (HUVEC) were isolated as previously
described [31,32]. Briefly, intact segments of 1 to 3-days-
old umbilical cords were drained, and the remaining
blood was rinsed from the umbilical vein with phosphate
buffered saline (PBS) via a blunt cannula attached at one
end of the vessel. The open end of the cord was sealed
and the cord distended with 1 mg/ml collagenase II and
incubated at room temperature for 30 min. The cord was
massaged and cut, and the collagenase digest collected.
The cells were washed, seeded into fibronectin-coated
flasks (1 μg human fibronectin per cm
2 flask) and grown
in Medium 199 media supplemented with 20% fetal calf
serum (FCS), 25 μg/ml heparin and 25 μg/ml endothelial
cell growth supplement (ECGS). Cells were subcultured
by trypsin-EDTA treatment and used until the fifth pas-
sage in the experiments.
Treatment of renal tumor cells with PKC inhibitors
The renal tumor cells CCF-RC1 and CCR-RC2 were
incubated with the PKC inhibitors GF109203X (inhibits
PKCa, bI, bII, g, δ and ε), GÖ6976 (inhibits PKCa, bI
and μ), RO31-8220 (inhibits PKCa, bI, bII, g and ε)
(concentrations of 1, 2 and 5 μM) and rottlerin (inhibits
PKCδ) (concentrations of 1, 5 and 10 μM, all from Cal-
biochem, La Jolla, USA) in serum free medium for
16 hours at 37°C in a humidified atmosphere containing
5% CO2 in air. The IC50 values of the inhibitors against
PKC isoforms are listed in Table 1. Serum free culture
medium without inhibitors served as a control. To ana-
lyze toxic effects of PCK inhibitors, renal tumor cells
were incubated with PKC inhibitors as described above,
each of them fourfold.
MTT cell vitality assay
The mitochondrial activity of the cells was assessed by a
MTT assay kit (Sigma, Deisenhofen, Germany). In this
assay the vitality of living cells was measured via mito-
chondrial dehydrogenases. The yellow MTT (3-[4,5-
dimethylthiazol-2-yl]2,5-diphenyl tetrazolium bromide)
was reduced to a blue formazan product by mitochon-
drial activity. Briefly, after incubation of the cells with
PKC inhibitors, culture medium was replaced by MTT
solution (0.5 mg/ml in phenol red free medium) and
incubated for two hours at 37°C. Afterwards, formazan
crystals were dissolved by MTT solubilization solution
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570 nm (reference wavelength 690 nm).
Cell adhesion assay
To analyze the adhesion of renal tumor cells to an
endothelial monolayer, HUVEC (1.5 × 10
4 cells/well)
were seeded into a 96 well plate coated with 1.5 mg/
cm
2 gelatine. Cells were allowed to grow to a confluent
monolayer within three days. PKC inhibitor-treated and
control CCF-RC1 cells were labeled by 10 μMB r d U
(Bromodeoxyuridine) for 30 min at 37°C. A cell suspen-
sion containing 10
4 cells was added to the endothelial
cell layer under presence of the particular PKC inhibitor
and incubated at 37°C in a humidified atmosphere con-
taining 5% CO2 in air. After two hours, non-adherent
cells were removed by washing with PBS. To normalize
the level of BrdU per cell, a defined number of 10
4
BrdU labeled tumor cells were centrifuged in parallel
into a 96 well plate. The relative amount of BrdU per
well was quantified as described in the next section.
Each experiment was performed eightfold and repeated
three times.
Analysis of cell proliferation
To study the effect of PKC inhibitors on proliferation, a
colorimetric BrdU incorporation assay (Roche, Mannheim,
Germany) was performed. Each 3 × 10
3 cells were seeded
in triplicate into a 96 well plate and treated in triplicate by
PKC inhibitors in serum free medium. BrdU solution
(10 μM) was added to the cells and incubated for two
hours at 37°C in a humidified atmosphere containing 5%
CO2 in air. After removing the culture medium, the cells
were fixed and the DNA was denatured in one step by
adding fixDenat solution. Incorporated BrdU was detected
by an anti-BrdU-POD antibody. The immune complex
was detected by a subsequent substrate reaction and quan-
tified by measuring the absorbance at 450 nm (reference
wavelength 690 nm).
Western blot analyses
For preparation of protein extracts, semiconfluent
CCF-RC1 and CCF-RC2 members were rinsed twice
with ice-cold phosphate-buffered saline (PBS) and
scraped off the dish with a rubber policeman in lysis
buffer on ice (20 mM HEPES, pH 7.7, 0.2 M NaCl,
1 . 5m MM g C l 2 ,0 . 4m ME D T A ,1 %T r i t o nX - 1 0 0 ,
0.5 mM DTT, 100 μg/ml leupeptin, 100 μg/ml aproti-
nin, 10 mM benzamidine, 2 mM phenylmethylsulpho-
nyl fluoride, 20 mM b-glycerophosphate and 0.1 mM
sodium-orthovanadate) [33]. Cell lysate was centrifuged
at 14,000 rpm at 4°C for 20 min. Protein concentra-
tions of the supernatants were determined using
Bicinchoninic acid reagents. Thirty μgp r o t e i n / l a n e
protein extract of the cells was separated by SDS-
PAGE (sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis) in 10% acrylamide gels and transferred by
semi-dry blotting onto polyvinylidene fluoride mem-
branes (PVDF, Immobilon P, Millipore, Bedford, MA).
The membrane was incubated with blocking solution
(Roth, Karlsruhe, Germany) for 1 h before incubation
with the primary antibodies against the PKCδ
(78 kDa), PKCε (83 kDa), PKCμ/PKD1 (115 kDa),
PDK2 (105 kDa) and PKCν/PDK3 (100 kDa) (all 1:300,
Santa Cruz, Heidelberg, Germany) overnight at 4°C.
After washing three times, the membrane was incu-
bated with horseradish peroxidase-conjugated goat
anti-rabbit secondary antibodies (Dako, Hamburg,
Germany) for 1 h at room temperature. The bound
antibodies were visualized by enhanced chemilumines-
cence (ECL, NEN Lifescience, Boston, USA) detection
system using Fuji medical X-ray film.
Flow cytometry
The integrin surface expression of untreated as well as
PKC inhibitor treated tumor cells was quantified by flow
cytometry. Briefly, cells were harvested in a 0.02% EDTA
solution and incubated with a monoclonal FITC labeled
anti-CD29 (b1 chain of integrins), anti-CD18 (b2c h a i n
of integrins), anti-CD61 (b3 chain of integrins) or an
isotypic control immunoglobuline (all Immunotech,
Hamburg, Germany), respectively, for 15 min, at 4°C in
darkness. Then, integrin expression was quantified on a
flow cytometer (BP Calibur, Becton Dickinson, Heidel-
berg, Germany).
Statistical analysis
For statistical confirmation, three or four independent
adhesion and proliferation experiments, each four- to
Table 1 IC50 values for GF109203X, GÖ6976, RO31-8220 (each nM) and Rottlerin (μM) for inhibition of PKC isoforms
(from: Goekjian and Jirousek, 1999 [35] and Gschwendt et al., 1994 [62])
Inhibitors PKC isoforms
ab I bII g δε h ξ μ
GF109203X [nM] 14 18 16 20 210 132 5800 2000
GÖ6976 [nM] 2.3 6.2 >10000 >10000 685 >10000 20
RO31-8220 [nM] 5 24 14 27 24
Rottlerin [μM] 30 42 40 3-6 100 82 100
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and a standard error were calculated from the results.
For significance analyses, SPSS 17.0 software was
applied. Differences in cell vitality, proliferation and
adhesion were performed using the Mann-Whitney
test. Differences were considered statistically significant
at p < 0.05.
Results
Cell vitality after PKC inhibition
Renal tumor cell vitality was determined by MTT assays.
With exception of GÖ6976 in CCF-RC2 cells, treatment
of renal cancer cells with the PKC inhibitors GF109203X,
GÖ6976, RO31-8220 (1, 2 and 5 μM) and rottlerin (1, 5
and 10 μM) did not influence cell vitality. Treatment of
CCF-RC2 cells with GÖ6976 resulted in a non-significant
reduced vitality to 68% of control (Figure 1).
Cell proliferation after PKC inhibition
To assess the influence of PKC inhibition on cell pro-
liferation, CCF-RC1 and CCF-RC2 cells were incubated
with the PKC inhibitors GF109203X, GÖ6976, RO31-
8220 and rottlerin in concentrations as described. Pro-
liferation was determined by BrdU incorporation. In
CCF-RC1 and CCF-RC2 cells we observed reduced cell
proliferation after treatment with RO31-8220 and
rottlerin in a concentration dependent manner. RO31-
8220 led to 58% (CCF-RC1, p = 0.057) and 68% (CCF-
RC2, p = 0.012) of control cell proliferation. After
rottlerin treatment, cell proliferation was reduced to
37% p = 0.029) and 45% (p = 0.012) of control mea-
surements in CCF-RC1 and CCF-RC2 cells, respec-
tively. In CCF-RC1 cells, also treatment with GÖ6976
resulted in a slightly reduced cell proliferation to 74%
of control (p = 0.200, Figure 2).
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Figure 1 Cell vitality after PKC inhibition. CCF-RC1 (A) and CCF-RC2 (B) cells were treated with PKC isoform specific inhibitors GF109203X,
GÖ6976, RO31-8220 and rottlerin in different concentrations, cell vitality was determined by MTT assay. Only treatment of CCF-RC2 cells with
GÖ6976 resulted in a slight reduction of cell vitality. The columns and bars represent mean value and standard error in % of control (untreated
cells).
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endothelial cells
For investigation of the adhesion of renal carcinoma
cells to endothelial cells, CCF-RC1 and CCF-RC2 cells
were treated with PKC inhibitors GF109203X, GÖ6976,
RO31-8220 and rottlerin as described and the adhesion
of these cells to a monolayer of HUVECs was deter-
mined. In CCF-RC1 cells, incubation with GÖ6976 and
RO31-8220 resulted in a concentration dependent inhi-
bition of cell adhesion to 55% (p = 0.029) and 45% (p =
0.029) of control cells, respectively. In contrast, CCF-
RC2 cells showed a reduced tumor cell - endothelial cell
adhesion after treatment also with GÖ6976 (50% of con-
trol, p = 0.029), whereas RO31-8220 resulted in no
alteration of cell adhesion (Figure 3).
Influence of PKC inhibitors on the expression of b1
integrins
Since tumor cell adhesion to endothelial cells by integ-
rins is mediated in the first line by b1, b2a n db3
integrins [34], the expression of these integrins was
determined by flow cytometry analysis. Both cell lines,
CCF-RC1 and CCF-RC2 cells, showed a clear expression
of b1 integrins, whereas neither b2n o rb3i n t e g r i n s
were expressed in these renal tumor cells (Figure 4). In
CCF-RC1 cells, b1 integrin levels were impaired by all
PKC inhibitors used in altered extent. GF109203X
induced a reduction of b1 integrin expression to 53%,
GÖ6976 to 52%, RO31-8220 to 8% and rottlerin to 73%
as compared to controls, respectively. In CCF-RC2 cells,
only GF109203X and RO31-8220 treatment resulted in
a 35% and 7% reduced b1 integrin expression as com-
pared to control expression levels (Figure 5). In our
experiment, RO31-8220 was the strongest inhibitior of
b1 integrins.
Expression of PKCδ, PKC and, PKCμ in CCF-RC2 cells and
PKD2 and PKD3 in both cell lines
In former investigations we showed an expression of
PKCδ, ε and μ in CCF-RC1 cells [19]. Since these three
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Figure 2 Cell proliferation after PKC inhibition. CCF-RC1 (A) and CCF-RC2 (B) cells were treated with the PKC isoform specific inhibitors
GF109203X, GÖ6976 and RO31-8220 in concentrations between 1 μM and 5 μM, and with Rottlerin in concentrations between 1 μM and
10 μM. The proliferation value is determined as a percentage of the proliferation of control (untreated cells). The columns and bars represent
mean value and standard error in % of control.
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Page 5 of 12isoforms seem to be relevant in metastatic processes of
renal cancer cells, we analyzed their expression in CCF-
R C 2c e l l s .F u r t h e r m o r e ,P K C 2a n d3w e r ea n a l y z e di n
both cell lines. Our Western blot analyses showed a
strong expression of PKCδ and, to a lesser extent, PKCε
and μ in CCF-RC2 cells (Figure 6). PKC2 and 3 (PKCν)
were not detectable in either cell line (data not shown).
Discussion
Renal cell carcinoma is a tumor entity with a high risk
for metastases and consequently carries a poor prog-
nosis. Therefore, investigations are based on the analysis
of metastatic mechanisms. Adhesion of tumor cells to
the endothelium of blood vessels during the process of
extravasation is one of the most important prerequisites
for the formation of metastasis. We investigated the
influence of various PKC isoforms on the regulation of
endothelial cell adhesion of the renal carcinoma cell
lines CCF-RC1 and CCF-RC2. The cells were incubated
with PKC isoform specific inhibitors GF109203X (inhi-
bits PKCa, bI, bII, g, δ and ε), GÖ6976 (inhibits PKCa,
bIa n dμ), RO31-8220 (inhibits PKCa, bI, bII, g and ε)
and rottlerin (inhibits PKCδ) [35]. Afterwards we quan-
tified cell adhesion to endothelial cells, cell proliferation
and the expression of b1, b2a n db3 integrins. In con-
trast to our former investigations [36], we pre-incubated
the cells with the PKC inhibitors for 16 hours. This
long-time incubation not only can lead to regulatory
response but also allows intracellular changes in gene
expression.
In CCF-RC1 cells treatment with GÖ6976 and
RO31-8220 resulted in a clearly reduced adhesion to
endothelial cells (55% and 45% of control, respectively).
Treatment of CCF-RC2 cells with GÖ6976 also led to
a reduced cell adhesion (50%), whereas RO31-8220
treatment had no impact on cell adhesion in this cell
line. The reducing effect of GÖ6976 on CCF-RC2 cells
must be interpreted with caution, since our MTT test,
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Figure 3 Cell adhesion to endothelial cells after PKC inhibition. Adhesion of CCF-RC1 (A) and CCF-RC2 (B) cells to a monolayer of human
umbilical endothelial cells (HUVEC) was measured after treatment with the PKC isoform specific inhibitors GF109203X, GÖ6976 and RO31-8220 in
concentrations between 1 μM and 5 μM, and with Rottlerin in concentrations between 1 μM and 10 μM. The adhesion value is determined as a
percentage of the adhesion of control (untreated cells). The columns and bars represent mean value and standard error in % of control.
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Page 6 of 12which determines the influence of the inhibitor on cell
vitality, also showed a slightly inhibitory effect of
GÖ6976 in CCF-RC2 cells (Figure 1B). The distinct
inhibitory effect of GÖ6976 in CCF-RC2 cells could
partly be a result of the cell toxicity of this agent,
causing a general reduction in cell vitality and conse-
quently reduced cell adhesion. However, GÖ6976
reduced tumor cell adhesion to endothelial cells in
both cell lines. The only PKC isoform which is
inhibited by GÖ6976, but not by GF109203X, nor
RO31-8220 or rottlerin, is PKCμ.P K D 2a n dP K C ν
(PKD3) are also inhibited by GÖ6076, although no iso-
form specific IC50 values for these PKD isoforms have
been published. Because PKD2 and PKCν/PKD3 are
not expressed in the cell lines tested, our results lead
to the assumption that PKCμ is involved in the regula-
tion of adhesion of the renal cancer cells CCF-RC1
and CCF-RC2.
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additionally classified as a member of a new protein
kinase family [23], has been shown to be activated
dependent on PKCε or PKCh [37,38]. In cancer cells,
PKCμ is known to be involved in metastasis. During
this process, PKCμ forms a complex with paxillin and
cortactin, leading to the formation of invadopodia,
initiating cell migration and degradation of the base-
ment membrane [39]. In this context, PKCμ mediated
cortactin phosphorylation [40]. On the other hand, the
loss of PKCμ expression increases the malignant
potential of breast cancer cells [41]. Syed et al. showed
that an overexpression of the subtype PKCμ1i np r o s -
tate carcinoma cells increased cell aggregation and
decreased cell motility [42]. This PKC isoform has
been shown to phosphorylate b-catenin, and conse-
quently also influences cell motility [43]. In accordance
with an important role in cell motility, PKCμ
also mediates integrin recruitment to newly formed
focal adhesions by promoting the recycling of avb3
integrin [44]. However, our study did not show any
expression of b3 integrins in CCF-RC1 and CCF-RC2
renal cancer cells; therefore, this mechanism could not
be studied.
I nC C F - R C 1c e l l s ,t r e a t m e n tw i t hG O 6 9 7 6r e s u l t e d
in a reduced expression of b1 integrins, leading to the
assumption that the effect of PKCμ on cell adhesion
occurs via b1 integrins. In contrast, no reduced b1
integrin expression was detectable in CCF-RC2 cells.
Assuming that this effect is not caused by a general
reduced cell vitality induced by GO6976, and as
detected by the MTT test performed in this study, a
further cell adhesion mechanism seems to take place
in this cell line. The adhesion of tumor cells to
endothelial cells is also regulated by other cell adhe-
sion molecules. The most significant integrin-indepen-
dent mechanism between the interaction of tumor
cells and endothelial cells is the binding of sialyl-Lewis
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endothelial cells. The expression of sialyl-Lewis × in
tumor cells is regulated by members of the a1,3 fuco-
syltransferase (a1,3FuT) family, and in particular by
FuT6 [45]. PKCμ has the ability to regulate the expres-
sion of FuT by inducing NFB [46]. In this way, an
inhibition of PKCμ should reduce the expression of
sLeX on the RCC cells. Since the expression of sLeX
on CCF-RC2 cells was less extensive compared to
CCF-RC1 cells [47], these cells may be more sensitive
to inhibition of sLeX. These mechanisms must be clar-
ified in further investigations.
In CCF-RC1 cells, in addition to GÖ6976, RO31-8220
also reduced adhesion to endothelial cells. PKCε is
reduced by RO31-8220 (IC50: 24 μM), but to a much
lesser extend by GF109203X (IC50: 132 μM), and not
by GÖ6976 or rottlerin. None of the PKC isoforms are
inhibited by GÖ6976 and RO31-8220, and not inhibited
by GF109203X or rottlerin at the same time (Table 1).
Therefore, in CCF-RC1 cells, in addition to PKCμ, PKCε
also seems to regulate the adhesion to endothelial cells.
Iaska and coworkers described a functional relationship
between PKCε activity and the membrane trafficking of
b1 integrins in fibroblasts [48]. After activation, PKCε
translocates to the cell membrane, where it colocalize
with b1 integrins at membrane ruffles. Furthermore,
inhibition of PKCε leads to accumulation of b1 integrins
in vesicles, suggesting a PKCε dependent step in the
trafficking of integrins [48]. Integrin trafficking is impor-
tant for recycling after internalisation. Impaired PKCε
dependent recycling reduces integrin expression on the
cell membrane. For this reason, we analyzed the expres-
sion of integrins on the cell surface of CCF-RC1 and
CCF-RC2 cells. And indeed, treatment with RO31-8220,
in contrast to the other PKC inhibitors used, showed a
strong inhibition of b1 integrin expression to 8% and
7% of control levels, respectively. This confirms earlier
results showing a reduced b1 integrin expression after
short time treatment of renal cancer cells with RO31-
8220 [19]. Therefore, the deficient recycling of b1i n t e g -
rins after treatment of tumor cells with RO31-8220 may
offer an explanation for the observation made in the
present study, i.e. that PKCε inhibition in both cell lines
tested results in a reduced expression of b1 integrins on
the cell membrane. Other authors also showed an invol-
vement of PKCε in cell adhesion and proliferation. For
instance, PKCε appears to be responsible for the regula-
tion of HeLa cell adhesion to the extracellular matrix
[20]. It is also implicated in b1 integrin-mediated adhe-
sion of human breast carcinoma cells to collagen [49].
In mammary carcinoma cells PKCε as well as PKCμ
have been shown to regulate cell adhesion to collagen
PKC PKC PKC
80 kD
100 kD
120 kD
60 kD
50 kD
40 kD
actin
220 kD
Figure 6 Expression of PKCδ, ε and μ in CCF-RC2 cells.E x p r e s s i o no fP K C δ (78 kDa), ε (83 kDa) and μ (115 kDa) in CCF-RC2 cell
was determined by Western blot (30 μg protein extract per lane). b-actin was used as loading control. All three PKC isoforms are expressed
in CCF-RC2 cells.
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Page 9 of 12IV in dependence of b1 integrins [44]. Furthermore,
Engers and coworkers suggested a role of PKCε in inva-
sion of renal carcinoma cells using a chick heart inva-
sion assay [50]. However, in contrast to others, this
study demonstrated a PKCε dependent adhesion to
endothelial cells.
The two cell lines investigated differ in origin, although
both were obtained from the same patient. CCF-RC1 was
established from the primary tumor and CCF-RC2 from
cells of the renal vein effluent of the perfused tumorous
kidney [30]. Both have been characterized as renal carci-
noma cells with similar characteristics, although CCF-
RC2 cells have already performed the first step of metas-
tasis, the detachment from the combined cell structure
and migration from the primary tumor. For this reason,
these cells are possibly more resistant against PKC inhibi-
tors, which may explain their different behavior.
Although PKCμ and PKCε are known to influence cell
proliferation [51-53], our investigations demonstrate a
distinct alteration in cell proliferation solely after treat-
ment of renal cancer cells with rottlerin, a PKCδ inhibi-
tor. PKCδ i sk n o w nt ob ei n v o l v e di nr e g u l a t i o no ft h e
cell cycle and apoptosis, and has also been shown to
play a role in renal cell carcinoma [54]. PKCδ induces
cell cycle arrest in many cell types by inhibiting the
expression of cyclin D1 and cyclin E and up-regulating
p27 [55-57]. Additionally, PKCδ activates DNA-PK
(DNA dependent protein kinase) [58], antagonizes the
Jak-STAT pathway and inhibits phospholipase D, an
antagonist of Raf [59]. On the other hand, an inhibition
of PKCδ induces apoptosis in B chronic lymphocytic
leukemia cells, whereas in healthy B cells a more anti-
apoptotic effect was mentioned [60]. In glioma cells an
inhibition of PKCδ by rottlerin also led to a reduced
activity of ERK and Akt, and inhibited cell proliferation
[61]. These findings show a strong cell specific effect of
PKCδ. Our results suggest a proliferation promoting
effect of PKCδ in renal carcinoma cells.
Conclusions
In conclusion, our results indicate that in CCF-RC1 and
CCF-RC2 cells, PKCμ regulates tumor cell adhesion to
umbilical vein endothelial cells. In CCF-RC1 cells, in
addition to PKCμ,P K C ε also regulates cell adhesion.
Our observation of b1 integrin expression being regu-
lated by PKCε, leads to the assumption that CCF-RC1
cell adhesion to endothelial cells is caused by affecting
the expression of b1 integrins. In contrast, cell prolifera-
tion seems to be regulated by PKCδ.
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